Overview

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
Phase:
PHASE1
Details
Lead Sponsor:
Beijing GoBroad Hospital